vs
Side-by-side financial comparison of FARMERS NATIONAL BANC CORP (FMNB) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $71.5M, roughly 1.2× FARMERS NATIONAL BANC CORP). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 3.2%). FARMERS NATIONAL BANC CORP produced more free cash flow last quarter ($52.2M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 6.2%).
Farmers National Banc Corp (OH) is a regional financial holding company based in Ohio, the United States. It offers full-spectrum retail and commercial banking products, wealth management solutions, and insurance services, primarily catering to individual consumers, small and medium-sized enterprises, and local community clients in Ohio and adjacent Midwestern U.S. regions.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
FMNB vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.5M | $86.8M |
| Net Profit | $14.6M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 24.8% | -84.7% |
| Net Margin | 20.5% | — |
| Revenue YoY | 3.2% | 17.7% |
| Net Profit YoY | 1.7% | — |
| EPS (diluted) | $0.39 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.5M | $86.8M | ||
| Q3 25 | $70.8M | $67.5M | ||
| Q2 25 | $69.8M | $60.0M | ||
| Q1 25 | $67.8M | $49.3M | ||
| Q4 24 | $69.3M | $73.7M | ||
| Q3 24 | $70.3M | $58.6M | ||
| Q2 24 | $66.5M | $31.1M | ||
| Q1 24 | $63.4M | $715.0K |
| Q4 25 | $14.6M | — | ||
| Q3 25 | $12.5M | $-91.3M | ||
| Q2 25 | $13.9M | $-111.7M | ||
| Q1 25 | $13.6M | $-116.2M | ||
| Q4 24 | $14.4M | — | ||
| Q3 24 | $8.5M | $-83.5M | ||
| Q2 24 | $11.8M | $-97.1M | ||
| Q1 24 | $11.2M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 24.8% | -84.7% | ||
| Q3 25 | 20.7% | -140.7% | ||
| Q2 25 | 23.4% | -189.8% | ||
| Q1 25 | 24.1% | -245.8% | ||
| Q4 24 | 25.5% | -117.5% | ||
| Q3 24 | 14.4% | -152.1% | ||
| Q2 24 | 21.3% | -327.6% | ||
| Q1 24 | 21.2% | -16464.6% |
| Q4 25 | 20.5% | — | ||
| Q3 25 | 17.6% | -135.3% | ||
| Q2 25 | 19.9% | -186.2% | ||
| Q1 25 | 20.0% | -235.5% | ||
| Q4 24 | 20.8% | — | ||
| Q3 24 | 12.1% | -142.7% | ||
| Q2 24 | 17.7% | -312.2% | ||
| Q1 24 | 17.7% | -15800.8% |
| Q4 25 | $0.39 | — | ||
| Q3 25 | $0.33 | — | ||
| Q2 25 | $0.37 | $-0.33 | ||
| Q1 25 | $0.36 | $-0.36 | ||
| Q4 24 | $0.38 | $-0.24 | ||
| Q3 24 | $0.23 | $-0.28 | ||
| Q2 24 | $0.31 | $-0.34 | ||
| Q1 24 | $0.30 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | $86.7M | — |
| Stockholders' EquityBook value | $485.7M | $698.6M |
| Total Assets | $5.2B | $913.2M |
| Debt / EquityLower = less leverage | 0.18× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M | ||
| Q1 24 | — | $356.2M |
| Q4 25 | $86.7M | — | ||
| Q3 25 | $86.6M | — | ||
| Q2 25 | $86.4M | — | ||
| Q1 25 | $86.3M | — | ||
| Q4 24 | $86.2M | — | ||
| Q3 24 | $86.0M | — | ||
| Q2 24 | $88.9M | — | ||
| Q1 24 | $88.8M | — |
| Q4 25 | $485.7M | $698.6M | ||
| Q3 25 | $465.9M | $702.3M | ||
| Q2 25 | $437.7M | $698.5M | ||
| Q1 25 | $429.1M | $767.9M | ||
| Q4 24 | $406.0M | $710.4M | ||
| Q3 24 | $439.7M | $773.5M | ||
| Q2 24 | $396.7M | $768.5M | ||
| Q1 24 | $397.0M | $680.0M |
| Q4 25 | $5.2B | $913.2M | ||
| Q3 25 | $5.2B | $904.9M | ||
| Q2 25 | $5.2B | $907.4M | ||
| Q1 25 | $5.2B | $966.7M | ||
| Q4 24 | $5.1B | $910.4M | ||
| Q3 24 | $5.2B | $991.1M | ||
| Q2 24 | $5.2B | $964.3M | ||
| Q1 24 | $5.1B | $869.8M |
| Q4 25 | 0.18× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.20× | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.22× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.0M | $-52.6M |
| Free Cash FlowOCF − Capex | $52.2M | $-61.9M |
| FCF MarginFCF / Revenue | 73.0% | -71.3% |
| Capex IntensityCapex / Revenue | 11.0% | 10.7% |
| Cash ConversionOCF / Net Profit | 4.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $85.8M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.0M | $-52.6M | ||
| Q3 25 | $10.7M | $-78.7M | ||
| Q2 25 | $14.0M | $-67.4M | ||
| Q1 25 | $15.7M | $-103.7M | ||
| Q4 24 | $66.6M | $-73.3M | ||
| Q3 24 | $23.9M | $-59.0M | ||
| Q2 24 | $16.6M | $-98.4M | ||
| Q1 24 | $13.7M | $-122.3M |
| Q4 25 | $52.2M | $-61.9M | ||
| Q3 25 | $9.0M | $-89.5M | ||
| Q2 25 | $12.4M | $-74.9M | ||
| Q1 25 | $12.2M | $-109.9M | ||
| Q4 24 | $54.9M | $-77.5M | ||
| Q3 24 | $20.4M | $-61.3M | ||
| Q2 24 | $14.4M | $-98.9M | ||
| Q1 24 | $12.2M | $-126.5M |
| Q4 25 | 73.0% | -71.3% | ||
| Q3 25 | 12.8% | -132.7% | ||
| Q2 25 | 17.8% | -124.9% | ||
| Q1 25 | 18.0% | -222.8% | ||
| Q4 24 | 79.2% | -105.1% | ||
| Q3 24 | 29.1% | -104.6% | ||
| Q2 24 | 21.6% | -317.9% | ||
| Q1 24 | 19.2% | -17685.3% |
| Q4 25 | 11.0% | 10.7% | ||
| Q3 25 | 2.4% | 16.1% | ||
| Q2 25 | 2.3% | 12.4% | ||
| Q1 25 | 5.2% | 12.6% | ||
| Q4 24 | 16.9% | 5.7% | ||
| Q3 24 | 4.9% | 3.9% | ||
| Q2 24 | 3.3% | 1.4% | ||
| Q1 24 | 2.4% | 583.4% |
| Q4 25 | 4.10× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 1.01× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 4.63× | — | ||
| Q3 24 | 2.80× | — | ||
| Q2 24 | 1.41× | — | ||
| Q1 24 | 1.22× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FMNB
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
